Growth hormone therapy in children with idiopathic short stature - the effect on appetite and appetite-regulating hormones: a pilot study.
Appetite Regulation
/ drug effects
Body Composition
/ drug effects
Body Height
/ drug effects
Child
Dwarfism
/ drug therapy
Energy Intake
/ drug effects
Energy Metabolism
/ drug effects
Female
Ghrelin
/ drug effects
Glucagon-Like Peptide 1
/ drug effects
Human Growth Hormone
/ administration & dosage
Humans
Insulin
/ metabolism
Leptin
/ metabolism
Male
Pilot Projects
Prospective Studies
Treatment Outcome
GLP-1
Ghrelin
Insulin
Leptin
standard meal test
Journal
Endocrine research
ISSN: 1532-4206
Titre abrégé: Endocr Res
Pays: England
ID NLM: 8408548
Informations de publication
Date de publication:
Historique:
pubmed:
7
7
2018
medline:
14
8
2019
entrez:
7
7
2018
Statut:
ppublish
Résumé
To investigate the effect of growth hormone (GH) therapy on appetite-regulating hormones and to examine the association between these hormones and the response to GH, body composition, and resting energy expenditure (REE). Nine pre-pubertal children with idiopathic short stature underwent a standard meal test before and 4 months following initiation of GH treatment. Ghrelin, GLP-1, leptin, and insulin levels were measured; area under the curve (AUC) was calculated. Height, weight, body composition, REE, and insulin-like growth factor levels were recorded at baseline and after 4 and 12 months. Following 4 months of GH therapy, food intake increased, with increased height-standard deviation score (SDS), weight-SDS, and REE (p < .05). Significant changes in appetite-regulating hormones included a decrease in postprandial AUC ghrelin levels (p = .045) and fasting GLP-1 (p = .038), and an increase in fasting insulin (p = .043). Ghrelin levels before GH treatment were positively correlated with the changes in weight-SDS (fasting: r = .667, p = .05; AUC: r = .788, p = .012) and REE (fasting: r = .866, p = .005; AUC: r = .847, p = .008) following 4 months of GH therapy. Ghrelin AUC at 4 months was positively correlated with the changes in height-SDS (r = .741, p = .022) and fat-free-mass (r = .890, p = .001) at 12 months of GH treatment. The reduction in ghrelin and GLP-1 following GH treatment suggests a role for GH in appetite regulation. Fasting and meal-AUC ghrelin levels may serve as biomarkers for predicting short-term (4 months) changes in weight and longer term (12 months) changes in height following GH treatment. The mechanisms linking GH with changes in appetite-regulating hormones remain to be elucidated. SDS: standard deviation score; REE: resting energy expenditure; SMT: standard meal test; AUC: area under the curve; ISS: idiopathic short stature; SGA: small for gestational age; FFM: fat-free-mass; FM: fat mass; EER: estimated energy requirements; DRI: dietary reference intakes; IQR: inter-quartile range.
Identifiants
pubmed: 29979896
doi: 10.1080/07435800.2018.1493598
doi:
Substances chimiques
Ghrelin
0
Insulin
0
Leptin
0
Human Growth Hormone
12629-01-5
Glucagon-Like Peptide 1
89750-14-1
Types de publication
Clinical Trial
Journal Article
Observational Study
Langues
eng